Legislature must regulate the role of drug benefit managers in our health care – The Boston Globe

College students who came of age during the COVID-19 pandemic and the Supreme Court’s decision to overturn Roe v. Wade acknowledge two very important things: first, access to high-quality health care is not something to be taken for granted, and second, geography matters. Unfortunately, these are lessons I learned from early childhood, when I developed juvenile arthritis after contracting a seemingly harmless virus, parvo, which triggers an immune reaction that triggers the condition in less than 1 percent of patients. As a result, while most 20-somethings are concerned with access…

Read More

Nivolumab with AVD Provides PFS Benefit Compared to Brentuximab Vedotin Plus AVD in Advanced Hodgkin Lymphoma

Treatment with nivolumab (Opdivo) combined with doxorubicin, vinblastine, and dacarbazine (AVD) resulted in prolonged progression-free survival (PFS) compared with brentuximab vedotin (Adcetris) plus AVD in patients with advanced-stage classic Hodgkin lymphoma (cHL ), according to the results of the Phase 3SWOG S1826 study (NCT03907488) presented at the 2023 ASCO Annual Meeting. At a median follow-up of 12.1 months, results showed that patients who received nivolumab plus AVD (n = 489) experienced an estimated 1-year PFS rate of 94% (95% CI, 91% -96%) versus 86% (95% CI, 82%-90%) among patients treated…

Read More